drugset / Trial / NCT07046273

Phase III Clinical Study on the Efficacy and Safety of Semaglutide and Ozempic® in Patients With Type 2 Diabetes

NCT07046273

Phase 3 Not yet recruiting 496 enrolled Shandong New Time Pharmaceutical Co., LTD
RandomizedParallel-groupOpen-labelTreatment

Summary

This study is a multicenter, randomized, open, parallel-controlled, Phase III clinical study aimed to evaluate the efficacy and safety of semaglutide injection and Ozempic® in patients with type 2 diabetes.

Timeline

Start
2025-08-01
Primary completion
2028-08-01
Completion
2029-02-01

Drugs

EvaluationDrugModalityDoseRoute
Subject F027 Unknown 1 mg
Comparator Semaglutide Peptide 1 mg